Our first studies verified that gefitinib and erlotinib in addition to their primary mechanism of targeting tumor cells harboring mutated forms of EGFR [20,21,22] also act as pro-oxidative stressors [23,24,25]. The gene discussed is EGFR; the disease is neoplasm.